Molecular Alterations in Pediatric Fibroblastic/Myofibroblastic Tumors: An Appraisal of a Next Generation Sequencing Assay in a Retrospective Single Centre Study
Restricted accessResearch articleFirst published online September, 2021
Molecular Alterations in Pediatric Fibroblastic/Myofibroblastic Tumors: An Appraisal of a Next Generation Sequencing Assay in a Retrospective Single Centre Study
Pediatric fibroblastic/myofibroblastic tumors (PFMTs) can be challenging to definitively classify. Large case series or diagnostic updates have not been recently published despite identification of molecular alterations that could improve diagnostic accuracy. Our review of the literature found that over two-thirds of the more than 30 types of PFMTs harbor recurrent molecular alterations. We performed an institutional review of PFMTs to highlight limitations of a predominantly morphological classification, and evaluated the utility of a next-generation sequencing assay to aid diagnosis.
Methods
PFMTs identified over a period of 12 years were reviewed, categorized per the new WHO classification, and tested using the Oncomine Childhood Cancer Research Assay.
Results
Eighty-seven specimens from 58 patients were reviewed; 50 were chosen for molecular analysis, 16 (32%) lacking definitive classification. We identified alterations, some novel, in 33% of assayed cases. Expected alterations were identified for most known diagnoses and mutations were identified in 6 of 16 tumors (38%) that were initially unclassified.
Conclusion
We confirmed a significant subset of PFMTs remain difficult to classify using current criteria, and that a combined DNA/RNA assay can identify alterations in many of these cases, improving diagnostic certainty and suggesting a clinical utility for challenging cases.
CoffinCMAlaggioR.Fibroblastic and myofibroblastic tumors in children and adolescents.Pediatr Dev Pathol. 2012;
15:127–180.
2.
HornickJL.Myofibroblastic tumors in children.Surg Pathol Clin. 2010;
3:653–688.
3.
WHO Classification of Tumours Editorial Board.WHO Classification of Tumors of Soft Tissue and Bone. 5th ed.Lyon, France:
IARC Press; 2020.
4.
FerrariASultanIHuangTT, et al.
Soft tissue sarcoma across the age spectrum: a population based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer. 2011;
57(6):943–949.
5.
CoffinCMDehnerLP.Fibroblastic-myofibroblastic tumors in children and adolescents: a clinicopathologic study of 108 examples in 103 patients.Fetal Pediatr Pathol. 1991;
11:569–588.
6.
Erikson-JohnsonMRChouMMEversBR, et al.
Nodular fasciitis: a novel model of transient neoplastia induced by MYH9-USP6 gene fusion.Lab Invest. 2011;
91:1427–1433.
7.
PatelNRChrisingerJSADemiccoEG, et al.
USP6 activation in nodular fasciitis by promoter-swapping fusions. Mod Pathol. 2017;
30:1577–1588.
8.
SalibCEdelmanMLillyJ, et al.
USP6 gene rearrangement by FISH analysis in cranial fasciitis: a report of three cases. Head and Neck Pathol. 2020;
14:257–261.
9.
PaulsonVAStojanovIAWasmanJK, et al.
Recurrent and novel USP6 fusions in cranial fasciitis identified by targeted RNA sequencing. Mod Pathol. 2020;
33:775–780.
10.
RakhejaDCunninghamJCMituiM, et al.
A subset of cranial fasciitis is associated with dysregulation of the Wnt/B-catenin pathway. Mod Pathol. 2008;
21:1330–1336.
11.
AntonescuCRSungYSZhangL, et al.
Recurrent SRF-RELA fusions define a novel subset of cellular variants in the myofibroma/myopericytoma spectrum: a potential diagnostic pitfall with sarcomas with myogenic differentiation.Am J Surg Pathol. 2017;
41:677–684.
12.
AgaimyABiegMMichalM,
Recurrent somatic PDGFRB mutations in sporadic infantile/solitary adult myofibromas but not in angioleiomyomas and myopericytomas.Am J Surg Pathol. 2017;
41:195–203.
13.
CheungYHGaydenTCampeauPM, et al.
A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet. 2013;
92:996–1000.
14.
KooSCJanewayKAHarrisMH, et al.
A distinctive genomic and immunohistochemical profile for NOTCH3 and PDGFRB in myofibroma with diagnostic and therapeutic implications.Int J Surg Pathol. 2020;
28:128–137.
15.
KnezevichSRMcFaddenDETaoW, et al.
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.Nat Genet. 1998;
18:184–187.
16.
ShengWQHisaokaMOkamotoS, et al.
A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol. 2001;
115:348–355.
17.
HallerFKnopfJAckermannA, et al.
Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol. 2016;
238:700–710.
18.
WongVPavlickDBrennanT, et al.
Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals a LMNA-NTRK1 gene fusion responsive to crizotinib. J Natl Cancer Inst. 2016;
108:2016–2018.
19.
WegertJVokuhlCCollordG, et al.
Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants.Nat Commun. 2018;
9:2378.
20.
KaoYCFletcherCDMAlaggioR, et al.
Recurrent BRAF gene fusions in a subset of pediatric spindle cell sarcomas: expanding the genetic spectrum of tumors with overlapping features with infantile fibrosarcomas. Am J Surg Pathol. 2018;
42:28–38.
21.
Tannenbaum-DvirSGlade-BenderJLChurchAJ,
Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma.Mol Case Stud. 2015;
1(1):a000471.
22.
ChurchAJCalicchioMLNardiV, et al.
Recurrent EML4-NTRK3 fusions in infantile fibrosarcomas and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;
31:463–473.
23.
CessnaMHZhouHSangerWG, et al.
Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases.Mod Pathol. 2002;
15:931–938.
24.
ChanJKCheukWShimizuM.Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol. 2001;
25:761–768.
25.
CoffinCMPatelAPerkinsS, et al.
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.Mod Pathol. 2001;
14(6):569–576.
26.
CookJRDehnerLPCollinsMH, et al.
Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;
25(11):1364–1371.
AntonescuCRSuurmeijerAJZhangL, et al.
Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;
39(7):957.
29.
TakahashiAKurosawaMUemuraM, et al.
Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.J Int Med Res. 2018;
46:3498–3503.
30.
AlassiriAHAliRHShenY, et al.
ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors.Am J Surg Pathol. 2016;
40:1051–1061.
31.
AlmanBLiCPajerskiME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;
151:329–334.
32.
AmaryMFCPauwelsPMeulemansE, et al.
Detection of β-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.Am J Surg Pathol. 2007;
31:1299–1309.
33.
BhattacharyaBDilworthHPIacobuzio-DonahueC, et al.
Nuclear β-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;
29:653–659.
34.
SawyerJRSammartinoGGokdenN, et al.
A clonal reciprocal t(2;7)(p13;p13) in plantar fibromatosis. Cancer Genet Cytogenet. 2005;
158:67–69.
35.
WehrliBMWeissSWYandowSCoffinCM.Gardner-associated fibromas (GAF) in young patients. Am J Surg Pathol. 2001;
25:645–651.
36.
CoffinCMHornickJLZhouHFletcherCDM.Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas.Am J Surg Pathol. 2007;
31:410–416.
37.
MichalM.Non-nuchal-type fibroma associated with Gardner’s syndrome: a hitherto-unreported mesenchymal tumor different from fibromatosis and nuchal-type fibroma. Pathol Res Pract. 2000;
196:857–860.
38.
MarksEEwartM.Infantile digital fibroma: a rare fibromatosis. Arch Pathol Lab Med. 2016;
140:1157–1162.
39.
RedlichGCMontgomeryKDAllgoodGAJosteNE.Plexiform fibrohistiocytic tumor with a clonal cytogenetic abnormality. Cancer Genet Cytogenet.1999;
208:141–143.
40.
SmithSFletcherCDMSmithMAGustersonBA.Cytogenetic analysis of a plexiform fibrohistiocytic tumor. Cancer Genet Cytogenet. 1990;
48:31–34.
41.
Leclerc-MercierSPedeutourFFabasT, et al.
Plexiform fibrohistiocytic tumor with molecular and cytogenetic analysis.Pediatr Dermatol. 2011;
28:26–29.
42.
KenneyBRichkindKEFriedlaenderGZambranoE.Chromosomal rearrangements in lipofibromatosis.Cancer Genet Cytogenet. 2007;
179:136–139.
43.
Al-IbraheemiAFolpeALPerez-AtaydeAR, et al.
Aberrant receptor tyrosine kinase signalilng in lipofibromatosis: a clinicopathological and molecular genetic study of 20 cases. Mod Pathol. 2019;
32:423–434.
44.
PulsFHofvanderJMagnussonL.FN1-EGF gene fusions are recurrent in calcifying aponeurotic fibroma.J Pathol. 2016;
238:502–507.
45.
LakshminarayananRKoniaTWelbornJ.Fibrous hamartoma of infancy: a case report with associated cytogenetic findings. Arch Pathol Lab Med. 2005;
129:520–522.
46.
RougemontALFetniRMurthySFournetJC.A complex translocation (6;12;8)(q25;q24.3;q13) in a fibrous hamartoma of infancy.Cancer Genet Cytogenet. 2006;
171:115–118.
47.
TassanoENozzaPTavellaE, et al.
Cytogenetic characterization of a fibrous hamartoma of infancy with complex translocations.Cancer Genet Cytogenet. 2010;
201:66–69.
48.
EllingtonNParkJYKingK, et al.
EGFR exon 20 insertion/duplication mutation in fibrous hamartoma of infancy with predominantly pseudoangiomatous pattern mimicking giant cell fibroblastoma.Int J Surg Pathol. 2017;
25:421–424.
49.
ParkJYCohenCLopezD, et al.
EGFR exon 20 insertion/duplication mutations characterize fibrous hamartoma of infancy.Am J Surg Pathol. 2016;
40:1713–1718.
50.
Dal CinPSciotRDe SmetLVan Den BergheH.Translocation 2;11 in a fibroma of tendon sheath. Histopathology. 1998;
32:433–435.
51.
RubinsteinAFitzhughVAhmedIVosbikianM. A case of a 14-year-old male with fibroma of tendon sheath of the hand with a novel chromosomal translocation 4;10. Case Rep Ortho. 2019;3514013.
52.
CarterJMWangXDongJ, et al.
USP6 genetic rearrangements in cellular fibroma of tendon sheath. Mod Pathol. 2016;
29(8):865–869.
53.
HanksSAdamsSDouglasJ, et al.
Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis.Am J Hum Genet. 2003;
73:791–800.
54.
DowlingODifeoARamirezMC, et al.
Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis.Am J Hum Genet. 2003;
73:957–966.
55.
RobinsonDRWuY-MKalyana-SundaramS, et al.
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;
45:180–185.
56.
ChmieleckiJCragoAMRosenbergM, et al.
Whole-exome sequencing identified a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;
45:131–132.
57.
GuillouLBenhattarJGenglerC, et al.
Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol. 2007;
31:1387–1402.
58.
MertensFFletcherCDMAntonescuCR, et al.
Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Investig. 2005;
85:408–415.
59.
ScanlanDRadioSJNelsonM, et al.
Loss of the PTCH1 gene locus in cardiac fibroma.Cardiovasc Pathol. 2008;
17:93–97.
60.
MacchiaGTrombettaDMollerE, et al.
FOSL1 as a candidate target gene for 11q12 rearrangements in desmoplastic fibroblastoma.Lab Investig. 2012;
92:735–743.
61.
AbrahamSCMontgomeryEAGiardielloFMWuTT.Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. Am J Pathol. 2001;
158:1073–1078.
62.
GuertlBBehamAZechnerR, et al.
Nasopharyngeal angiofibroma: an APC-gene-associated tumor?Hum Pathol. 2000;
31:1411–1413.
63.
SaitoATaketaniTKanaiR, et al.
A case with sacrococcygeal primitive myxoid mesenchymal tumor of infancy: a case report and review of the literature. J Pediatr Hematol Oncol. 2013;
35:e280–e282.
64.
WangHLiuQWangJ, et al.
Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic study of 3 additional cases. Chinese J Pathol. 2014;
43:375–378.
65.
CiprianiNARyanDPNielsenGP.Primitive myxoid mesenchymal tumor of infancy with rosettes: a new finding and literature review.Int J Surg Pathol. 2014;
22:647–651.
66.
SantiagoTClayMRAllenSJOrrBA.Recurrent BCOR tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. Mod Pathol. 2017;
30:884–891.
67.
KaoYCSungY-SZhangL, et al.
Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B fusions in soft tissue undifferentiated round cell sarcoma of infancy: overlapping genetic features with clear cell sarcoma of kidney. Am J Surg Pathol. 2016;
40:1009–1020.
68.
MengGZZhangHYZhangZ, et al.
Myofibroblastic sarcoma vs nodular fasciitis: a comparative study of chromosomal imbalances.Am J Clin Pathol. 2009;
131:701–709.
69.
LimonJSzadowskaAIliszkoM, et al.
Recurrent chromosome changes in two adult fibrosarcomas. Genes Chrom Cancer. 1998;
123:119–123.
70.
BourgeoisJMKnezevichSRMathersJASorensonPHB.Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;
24:937–946.
71.
OgoseAKawashimaHUmezuH, et al.
Sclerosing epithelioid fibrosarcoma with der(10)t(10;17)(p11;q11).Cancer Genet Cytogenet. 2004;
152:136–140.
72.
ImadaHYamaguchiTIidaSUedaY.A case of sclerosing epithelioid fibrosarcoma with EWSR1 translocation. AJSP: Rev Rep. 2017;
22:171–174.
73.
PulsFAgaimyAFluckeU, et al.
Recurrent fusions between YAP1 and KMT2A in morphologically distinct neoplasms within the spectrum of low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma.Am J Surg Pathol. 2020;
44:594–606.
74.
KaoYLeeJCZhangL, et al.
Recurrent YAP1 and KMT2A gene rearrangements in a subset of MUC4-negative sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2020;
44:368–377.
75.
LambertIDebiec-RychterMGuelinckxP, et al.
Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes. Virchows Arch. 2001;
438:509–512.
76.
AntonescuCRZhangLNielsenGP, et al.
Consistent t(1;10) with rearrangements of TFFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer. 2011;
50:757–764.
77.
HallorKHSciotRStaafJ, et al.
Two genetic pathoways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumor, and morphologically similar lesions.J Pathol. 2009;
217:716–727.
78.
KresseSHOhnstadHOBjerkhagenB, et al.
DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridixation. PLoS One. 2010;
5:1–10.
79.
IdbaihACoindreJMDerreJ, et al.
Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share similar genomic imbalances.Lab Investig. 2005;
85:176–181.
80.
LeeJCLiCFFangFM, et al.
Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol. 2010;
23:1379–1392.
81.
NakayamaRNemotoTTakahashiH, et al.
Gene expression analysis of soft tissue sarcaoms: characterization and reclassification of malignant fibrous histiocytomas. Mod Pathol. 2007;
20:749–759.
82.
MentzelTKutznerH.Dermatomyofibroma: clinicopathological and immunohistochemical analysis of 56 cases and reappraisal of a rare and distinct cutaneous neoplasm.Am J Dermatopathol. 2009;
31:44–49.
83.
MacarenoRSZamolyiRFrancoMF, et al.
Genomic gains of COL1A1-PDFGB occu in the histologic evoluation of giant cell fibroblastoma into dermatofibrosarcoma protuberans. Genes Chromosomes Cancer. 2008;
47:260–265.
84.
FetschJFMiettinenMLaskinWB, et al.
A clinicopathological study of 45 pediatric soft tissue tumros with an admixture of adipose tissue and fibroblastic elements, and a proposal for classification as lipofibromatosis. Am J Surg Pathol. 2000;
24:1491–1500.
85.
PavlickDShrockABMalickiD, et al.
Identification of NTRK fusions in pediatric mesenchymal tumors.Pediatr Blood Cancer. 2017;
64(8):e26433.
HiemenzMCOstrowDGBusseTM, et al.
OncoKids: A comprehensive next-generation sequencing panel for pediatric malignancies. J Mol Diagn. 2018;
20:765–776.
88.
BakkerASlackJCarageaM, et al.
Adipocyte-rich CTNNB1-mutated intramuscular Gardner fibroma progressing to desmoid fibromatosis.Pediatr Dev Pathol. 2021;
24:62–67.
89.
GustafsonP.Soft tissue sarcoma: epidemiology and prognosis in 508 patients. Acta Orthop Scand.1994;
65(Suppl 259):2–31.
90.
Mariño-EnriquezAWangWRoyA, et al.
Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.Am J Surg Pathol. 2011;
35:135–144.
91.
DavisJLLockwood CmStohrB, et al.
Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors.Am J Surg Pathol. 2019;
43:435–445.
92.
AgaramNPZhangLSungT, et al.
Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors.Am J Surg Pathol. 2016;
40:1407–1416.
93.
KurodaNTrpkovKGaoY, et al.
ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.Mod Pathol. 2020;
33:2564–2579.
94.
PinsolleJMondetJDuruisseauxM, et al.
A rare fusion of CLIP1 and ALK in a case of non-small cell lung cancer with neuroendocrine features. Clin Lung Cancer. 2019;
20:535–540.
95.
VendrellJATaviauxSBegantonB, et al.
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.Sci Rep. 2017;
7:12510–
96.
YehIde la FouchardiereAPissalouxD, et al.
Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.Am J Surg Pathol. 2015;
39:581–591.
97.
ZreikRTFritchieKJ.Morphologic spectrum of desmoid-type fibromatosis. Am J Clin Pathol. 2016;
145(3):332–340.
98.
PinkerBMRenieD.A subcutaneous manifestation of tuberous sclerosis complex in the posterior scalp.Oral Maxillofac Surg Cases. 2019;
5:100127.
99.
ElderDEMassiDScolyerRAWillemzeR, eds. WHO Classification of Skin Tumors. 4th ed.
Lyon, France:
International Agency for Research on Cancer; 2018.
100.
MoosaviCJhaPFanburg-SmithJC.An update on plexiform fibrohistiocytic tumor and addition of 66 cases from the Armed Forces Institute of Pathology, in honor of Franz M. Enzinger, MD.Ann Diagn Pathol. 2007;
11:313–319.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
